Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Clinical trial NCT07032727 · RECRUITING

Trial details

NCT number: NCT07032727
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Targeted Therapy IDH1-Mutated Malignancies Mutations

Start date: 2025-09-12
Primary completion: 2027-06-01
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.